

Complete if Known Substitute for form 1449A/PTO 10/686,619 Application Number INFORMATION DISCLOSURE October 17, 2003 Filing Date STATEMENT BY APPLICANT Margot Mary O'TOOLE et al. First Named Inventor (use as many sheets as necessary) 1614 Art Unit Theresa Frederick Examiner Name Sheet 1 of 4 Attorney Docket Number 031896-004000 (AM100990)

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KS	 	US-6280941	08/28/2001	Tsao et al.	
		US-4690905	09/01/1987	Diamond et al.	
		US-5919619	07/06/1999	Tullis	
		US-6506559	01/14/2003	Fire et al.	
		US-4935233	06/19/1990	Bell et al.	
		US-4751180	06/14/1988	Cousens et al.	
		US-4980281	12/25/1990	Housey	
		US-5266464	11/30/1993	Housey	
		US-5688635	11/18/1997	Parker et al.	
		US-5877007	03/02/1999	Housey	
		US-4671958	06/09/1987	Rodwell et al.	
		US-4489710	12/25/1984	Spitler	
		US-4625014	11/25/1986	Senter et al.	
		US-4638045	01/20/1987	Kohn et al.	
		US-4671958	06/09/1987	Rodwell et al	
		US-4569789	02/11/1986	Blattler et al.	
		US-5498531	03/12/1996	Jarrell	
1		US-5459039	10/17/1995	Modrich et al.	
V		US-4522811	06/11/1985	Eppstein et al.	

		FC	REIGN PATENT	DOCUMENTS		
Examiner Cite Initials No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
		Country Code ³ Number ⁴ (if known)	MM-DD-YYYY		Relevant Passages or Relevant Figures Appear	τ•
KS		WO-99/14346	03/25/1999	Woolf		
		WO-01/70949	09/27/2001	Graham et al.		
		WO-01/36646	05/25/2001	Zernicka-Goetz et al		
		WO-00/63364	10/26/2000	Pachuk et al.		
		WO-00/44895	08/03/2000	Kreutzer et al		
		WO-01/75164	10/11/2001	Tuschl et al.		
		WO-01/92513	12/06/2001	Arndt et al.		
		WO-01/68836	09/20/2001	Beach et al.		
		WO-01/29058	04/26/2001	Mello et al.		
		WO-97/07668	03/06/1997	Campbell et al.		
W		WO-97/07669	03/06/1997	Campbell et al.		
_		WO-89/10134	11/02/1989	Pardridge et al.		

	WU-89/10134	11/02/1969	Faidridge et al.		
Examiner Signature	/Katherine	Salmon/	Date Considered	08/24/2006	

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

S	hstitut	e for form	1449B'PTO				Complete if Known	
-						Application Number	10/686,619	
l II	NFO	RMA	TION I	DISC	LOSURE		October 17, 2003	
S	TAT	TEME	ENT BY	APP	PLICANT	Filing Date	Margot Mary O'TOOLE	et al
		(use as	many sheets o	zs necess	ar;·)	First Named Inventor Group Art Unit	1614	
							Theresa Frederick	
		2		Of	14	Examiner Name		
Sh	ccı	2		L	<u> </u>	Attorney Docket Number	031896-004000 (100990	"
<u> </u>		0:-				RT - NON PATENT LITERATU		
Exam Initia		Cite No. ¹		item (b	ook, magazine, joun	nal, serial, symposium, catalog, etc. publisher, city and/or country whe	. <u> </u>	T ²
K	S				OULUS, A. N Today 15:150-		unity: Part Ii. Genetic Predisposition,	
			SUN et	al., <i>J</i> .	Neuropathol I	Exp Neurol, 56:1339-134	8, 1997	
├─┤		 	KADO	MATC	Iletal Re I	Cancer, 75:354-359, 199	7	+
			KADO	WIAIS	50 Ct al., Di 5	Cancer, 13.334-339, 199	,	
			CHOU	DHUR	ll et al., Cance	r Res., 75:354-359, 1997		
ŀ								
			TAKEI	et al.,	Cancer Res.,	61:8486-8491, 2001		
			TAKEI	et al.,	J. Biol Chem	Embo J, 16:6936-6946,	1997	
			ווטאו, ז	ATSU	JYA, et al., Pe	ptide Institute Inc., J Pep	ot Sci 2:28-39, 1996	
			MURA	MATS	SU et al., <i>Bioci</i>	hem Biophys Res Commu	ın 203:1131-1139, 1994	
			ASAI e	t al., <i>B</i>	Biochem Bioph	ys Res Commun, 203:113	31-1139, 1994	
			KANEI	DA et	al., <i>Biochem B</i>	iophys Res Commun, 220	0:108-112, 1996	
			PEDRA	ZA et	al., J Biochen	ı, 117: 845-849, 1995		
			AHME	D et al	., Cancer Lett,	, 180: 159-63, 2002		
			AHME	D et al	., Int. J. Mol. I	Med., 6:281-287, 2000		
			URIOS	et al.,	Biochem Biop	ohys Res Commun 175: 6	517-627, 1991	
1	/		NAIR e	t al., ^	Veuroscience, S	85:759-771, 1998		

Complete if Known Substitute for form 1449A/PTO 10/686,619 Application Number INFORMATION DISCLOSURE October 17, 2003 Filing Date STATEMENT BY APPLICANT Margot Mary O'TOOLE et al. First Named Inventor (use as many sheets as necessary) 1614 An Unit Theresa Frederick Examiner Name Sheet 3 Of 4 Attorney Docket Number 031896-004000 (AM100990)

	<u> </u>							(/(////////////////////////////////////
		SUI et a	al., Pro	c. Nat'l. Acc	ad. Sci. USA,	99: 5515-5520,	2002	
KS								
1		LEE et	al., <i>Na</i>	ture Biotech	nology, 20:50	0-505, 2002		
						=:		
		NEEDI	LEMA]	N and WUN	SCH, J. Mol.	Biol., 48:444-4	153, 1970	
		ALTSC	HUL	et al., Polyni	icleotides Res	25 (17): 3389-	3402, (1997).	
		MARA	TEA e	t al., Gene, 4	10:39-46, 198	5		
						VIG 4 .02 .0250	00/0 100/	
		MURP	HY et a	al., <i>Proc. Na</i>	it'l Acad. Sci.	USA, 83:8258-	8262, 1986	
		DELGI	RAVE	et al., <i>Protei</i>	in Engineering	3, 6: 327-331, 1	1993	
		GOSSE	N et a	., Science, 2	268: 1766-176	9, 1995		
		NO	1 0	- 21-47 4	-J Co: 1/54 (93: 3346-3351,	1006	
		NO et a	11., <i>Pro</i>	c. Nai I. Act	ш. эсі. Озя, :	73. 3340-3331,	1990	
		WANG	et al.,	Nat. Biotec	h, 15: 239-243	3, 1997		
	İ							
		YE et a	l., Scie	nce 283: 88	-91, 1999			
	ļ	ZUCKI	CDMA	NN et al 10	OA I Med C	hem. 37:2678-8	RS	
		ZUCKI	CRIVIA	iviv et al. 19	774, J. Meu. C	nem. 57.2070-0		
	<u> </u>	LAM,	Antica	cer Drug D	es., 12: 145, 1	997		
		GUAT	ELLI e	t al., <i>Proc. l</i>	Vatl. Acad. Sc	i. USA, 87: 187	74-1878, 1990	
_	-	KWOL	l et al	Proc Natl	Acad Sci 119	A, 86: 1173-11	77. 1989	
		KWOII	. o. ai.,		7.0au. oc O	, 50. 11.5-11	,	
1,	 	LIZAR	DI et a	I. Q-Beta R	eplicase, Bio-	Technology 6:	1197, 1988	
V								

Substitute	e for form	1449A/PTO				Complete if Known
TNEO	TO B # A	TIONIT	Mec	COUDE	Application Number	10/686,619
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 17, 2003
STAT	STATEMENT BY APPLICANT (use as many sheets as necessary)		First Named Inventor	Margot Mary O'TOOLE et al.		
	(we as	many sheets o	и песеци	(בייני)	Art Unit	1614
					Examiner Name	Theresa Frederick
Sheet	4		Of	4	Attorney Docket Number	031896-004000 (AM100990)
KS		MYER	S et al.	, Science, 230	: 1242, 1985	
		KEEN	et al., i	Trends Genet,	7:5, 1991	
		ROSEN	\BAU	M and REISS	NER, Biophys Chem 265: 1	2753, 1987
		SAIKI	et al.,	Proc. Natl. Acc	ad. Sci USA, 86:6230, 1989	
-	-	O'GOR	MAN	et al., Science	, 251:1351-1355, 1991	
		WILM	UT, I.	et al., Nature 3	385:810-813, 1997	
		LOCK	HART	et al., Nature	Biotechnology, 14, 1675-80), 1996
1/		HILL e	t al., C	Genome Biol. 2	Res, 0055.1-0055.13, 200	1

1 Signature 1	Examiner Signature	/Katherine Salmon/	Date Considered	08/24/2006	╝
---------------	-----------------------	--------------------	--------------------	------------	---

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

OIPE	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
E EB 23	AUR AND
(X).	~~

2

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

C	Complete if Known					
Application Number	10/686,619					
Filing Date	October 17, 2003					
First Named Inventor	Margot Mary O'TOOLE et al.					
Art Unit	- 1614					
Examiner Name	Theresa Frederick					
Attorney Docket Number	031896-004000 (AM100990)					

			U.S. PATENT DOC	UMENTS	
Examiner Initials	Cite No. [†]	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columna, Lines, Where Relevant Passages or Relevant Figures Appear

		FC	REIGN PATENT I	OCUMENTS		
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ³ Country Code ³ Number (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
KS		EP 1 215 500 A	06-19-2002	Muramatsu		

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
KS		MISHIMA, et al., "Increased expression of midkine during the progression of human astrocytomas", Neuroscience Letters, Vol., 233, No. 1, pages 29-32, (1997)	
		TSUTSUI, et al., "A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas", Cancer Research, Vol. 53, No. 6, pages 1281-1285, (1993)	
		KUROSAWA, et al., "Midkine binds specifically to sulfatide. The role of sulfatide in cell attachment to midkine-coated surfaces", European Journal of Biochemistry, Vol. 267, No. 2, January 2000	
		ZOU, et al., "A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican", European Journal of Biochemistry, Vol. 267, No. 13, July 2000	
		SAID, et al., "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 40, pages 37492October 4, 2002	
		STOICA, et al., "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 39, pages 35990-35998, September 27, 2002	:
\bigvee		IKEDA, et al., "Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence", <i>Biology of Reproduction</i> , Vol. 63, No. 4, pages 1067-1074, October 2000	

Substitute for form 1449A/PTO PRADENARY

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

Sheet

2

Complete if Known					
Application Number	10/686,619				
Filing Date	October 17, 2003				
First Named Inventor	Margot Mary O'TOOLE et al.				
Art Unit	1614				
Examiner Name	Theresa Frederick				
Attorney Docket Number	031896-004000 (AM100990)				

			U.S. PATENT DOC	UMENTS				
Examiner Initials	Cite No.'	U.S. Patent Document Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wh Passages or Relevant Figu			
	Ι							
•			FOREIGN PATENT D	OCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document Kind Coc Country Code ¹ Number ⁴ (if know		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	. <u>T</u> *		
		1		•				
		OTHER PRIC	DR ART – NON PATENT L	ITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.						
ĶS		KATO, et al., "Increased midkine expression in intrahepatic cholangiocarcinoma: Immunohistochemical and in situ hybridization analyses", <i>Liver</i> , Vol. 20, No. 3, June 2000						
KS		Midkine MK Sequences	Between the Human	Binding Factors Strong Con and the Mouse", <i>Biochemi</i> , 176, No. 2, pages 792-797,	cal and			

Examiner	/Katherine Salmon/	Date	09/05/2006
Signature	/ Racifer Inc Darmon/	Considered	,,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222 uspto gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The state of the s	THE SOLUTION OF THE PARTY OF TH
E TR	ADENIA Costitute for for

	<u> </u>									
TRACE	e for form 14	49A/PTO				Complete	if Know	n		
INFORMATION DISCLOSURE			Application Number 10		10/68	10/686,619				
STATEMENT BY APPLICANT				Filing Date		Octob	er 17, 2003			
SIA		_		1	First Named Ir	ventor	Margo	t Mary O'TOOLE	et al.	
	(use as m	any sheets as nece	sary)		Art Unit		1614			
					Examiner Nam	ne	There	sa Frederick		
Sheet	1	of	1		Attorney Dock	et Number	03189	6-004000 (AM1009	90)	
	<u></u>			11	LS. PATENT DOC	IMENTS				
Examiner	- Civi	U.S. Patent I	locument		AS. TATENT DOC	J.111.11.15		Ĭ .		
Examiner Initials	Cite No. ¹				Publication Date MM-DD-YYYY				Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Co	le' (if known)		MM-DD-1111	Applicant of Cited Docu	meni	Passages of Activative Figures App		
	- 							}		
							-			
			<u> </u>	FOR	EIGN PATENT D	OCUMENTS				
Examiner	Cite	No.1 Kind Code ³		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
Initials*	No.							T ⁶		
		Country Code N	umber⁴ (if kno	(mm)						
		<u> </u>								
·			OTHER PRIC)R AR	RT – NON PATENT L	ITERATURE DOCUMEN	TS			
Examiner	Cite	Inc	ude name of the	autho	or (in CAPITAL LETTE	RS), title of the article (whe	n appropris	ite), title of the	T²	
Initials*	No.1				mal, serial, symposium,	catalog, etc.)., date, page(s) country where published.			1 '	
					publisher, City and/or	country where published.			+	
KS			International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages							
-		ASALT	ASAL Total "Identification of honorin hinding sites in midking and their role in							

Examine: Initials	r Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.			
KS		International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages			
		ASAI, T. et al., "Identification of heparin-binding sites in midkine and their role in neurite-promotion," Biochem. Biophys. Res. Commun., 236(1):66-70 (1997)			
		IWASAKI, W. et al., "Solution structure of midkine, a new heparin-binding growth factor," EMBO J., 16(23):6936-6946 (1997)			
		MYERS, E.W. and MILLER, W., Optical alignments in linear space, CABIOS, 4(1):11-17 (1988)			
		MURAMATSU, H. et al., "Localization of heparin-binding, neurite outgrowth and antigenic regions of midkine molecule," Biochem. Biophys. Res. Commun., 203(2):1131-1139 (1994)			
V	TAKEI, Y. et al., "5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine, its design and application for cancer therapy," J. Biol. Chem., 277(26):23800-23806 (2002)				

Examiner
Signature /Katherine Salmon/ Considered 08/24/2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.



	ADE	on ITA					
Substitute for form 1449A/PTO			Complete if Known				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number			10/686,619		
		Filing Date			per 17, 2003		
	(use as i	many sheets as necessary)	First Named	Inventor		ot Mary O'TOOLE	et al.
			Art Unit		1634		
			Examiner Na			fer Shin Shin Wong	
Sheet	1	of 2	Attorney Do	cket Number	03189	96-004000 (AM100	1990)
		1	J.S. PATENT DO	CUMENTS			
Examiner Initials	Cite No.	U.S. Patent Document	Publication Date	Name	of Patentee or	Pages, Columns, Line	s, Where
tin uars	1.00	Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant	of Cited Document	Relevant Passages or Figures Appe	
KS		U.S 4,554,101	11-19-1985	HOPP, T. F	<u>. </u>		
K.C.		U.S 2003/0148298 A1	08-07-2003	O'TOOLE,	M. et al.		
Examiner	T			Date	·		
Signature				Considered			
		FOI	REIGN PATENT	DOCUMENTS	 		
Examiner Initials	Cite No. ¹	Foreign Patent Document Kind Code ³	Publication Date MM-DD-YYYY	Name of Pat Applicant of Cite		ages, Columns, Lines, Where elevant Passages or Relevant Figures Appear	π•
KS	 	Country Code ³ Number ⁴ (If known) WO 2004/036221 A2	04-29-2004	O'TOOLE et	al.		
Examiner	† 			Date			
Signature	<u> </u>			Considered			
		OTHER PRIOR ART	- NON PATENT	LITERATURE	DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author item (book, magazine, jour	(in CAPITAL LETTI nal, serial, symposium publisher, city and/or	, catalog, etc.)., date	, page(s), volume-iss	e), title of the sue number(s),	T,
		FRAMPTON, G. et al., Iden					
KS		systemic lupus erythematos protein P0 as an endothelial 2000	us using a mole cell autoantige	cular cloning s n, <i>Rheumatolo</i>	strategy: a role ogy (Oxford), 3	for ribosomal P 9(10):1114-1120,	
-		ADACHI, M., et al., Correla patients with non-small cell					
		DUAN, J. et al., Proposed li and site-directed mutagenes	ipocalin fold for	apolipoprote	in M based on		
		HAMMOND, C. et al., The				C class II	1
	compartments where it associates with HLA-DR, -DM, and -DO molecules, J. Immunol., 161(7):3282-3291, 1998						
	HECKENLIVELY, J. R. et al., Autoimmune retinopathy: patients with antirecoverin immunoreactivity and parretinal degeneration, Arch. Ophthalmol., 118(2):1525-1533,						
	2000						
	LAGAUDRIERE-GESBERT, C. et al., The tetraspanin protein CD82 associates with both free HLA class I heavy chain and heterodimeric beta 2-microglobulin complexes, J.						
		Immunol., 158(6):2790-279	D82, member o	of the tetra-spa	in-transmembr	ane protein family,	
		is a costimulatory protein fo MAEDA, A. et al., Vaccina					
V		induces autoimmune retinal <i>Immunol.</i> , 32:2300-2307, 20	dysfunction an				
Examiner Signature		/Katherine Sal		Date Considered	09	/05/2006	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/686,619	
STATEMENT BY APPLICANT				Filing Date	October 17, 2003	
SIA	(use as many sheets as necessary)		First Named Inventor	Margot Mary O'TOOLE et al.		
	(100	,	-,,	Art Unit	1634	
				Examiner Name	Jennifer Shin Shin Wong	
Sheet 2 of 2		Attorney Docket Number	031896-004000 (AM100990)			

	1.	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	T²				
Examiner Initials No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		ROTH, W. et al., Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells, Oncogene, 19(37):4210-4220, 2000					
		XU, N. et al., Effects of platelet-activating factor, tumor necrosis factor, and interleukin- lalpha on the expression of apolipoprotein M in HepG2 cells, Biochem. Biophys. Res. Commun., 292(4):944-950, 2002					
		XU, N. et al., A novel human apolipoprotein (apoM), J. Biol. Chem., 274(44):31286-31290, 1999					
		YOSHINO, K. et al., Secreted Frizzled-related proteins can regulate metanephric development, Mech. Dev., 102(1-2):45-55, 2001					
		LEE, N. S. et al., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, Nat. Biotechnol., 20(5):500-505, 2002					
		BAZHIN, A. V. et al., Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision, Lung Cancer, 34(1):99-104, 2001					
		International Search Report for International Application No. PCT/US2004/005655, mailed November 8, 2004, 6 sheets					
		ROZZO, S. J. et al., Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus, <i>Immunity</i> , 15(3): 435-443, 2001					
		MOSER, K. L. et al., The use of microarrays to study autoimmunity, J. Investig. Dermatol. Symp. Proc., 9(1):18-22, 2004					
V		BENNETT, L. et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, J. Exp. Med., 97(6):711-723, 2003					

Examiner	/7-4h/	Date	09/05/2006
Signature	/Katherine Salmon/	Considered	0370372000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.